{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:32Z","timestamp":1792801952493,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Testosterone replacement therapy is commonly used in transgender men for masculinization. One of the most common adverse effects of testosterone replacement therapy is androgenetic alopecia. In Japan, finasteride is approved exclusively for cisgender men and is not indicated for transgender men. The aim of this clinical trial was to evaluate the safety and efficacy of finasteride in transgender men with androgenetic alopecia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>This study included three transgender men (assigned female at birth, identifying as male), aged 44, 43, and 29\u00a0years. All participants were of Asian ethnicity. A clinical trial was conducted from October 2021 to December 2023. Transgender men aged 20\u201360\u00a0years who had not undergone hysterectomy, were undergoing testosterone replacement therapy, and who had been diagnosed with stage\u2009\u2265\u2009II androgenetic alopecia on the basis of the Norwood\u2013Hamilton scale were recruited. The participants initiated treatment with 0.2\u00a0mg of finasteride per day for 3\u00a0months (phase 1). If no adverse events above grade 2 occurred, the dose was increased to 1.0\u00a0mg per day for an additional 3\u00a0months (phase 2). The primary endpoints were the incidence of treatment-related adverse events at 1\u00a0week, 1\u00a0month, and 3\u00a0months, as well as the rate of participants continuing treatment at 3\u00a0months. None of the patients experienced serious adverse events at 3\u00a0months, and all the patients extended their treatment to a total of 6\u00a0months. Improvements of at least one stage on the N\u2013H scale were observed, but two participants experienced resumption of menstruation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Finasteride appears to be a safe and effective treatment for androgenetic alopecia in transgender men undergoing testosterone replacement therapy. However, its potential for reducing some of the effects of testosterone replacement therapy warrants further investigation. Trial registration: jRCT, jRCTs061210040, registered 7 October 2021, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCTs061210040\" ext-link-type=\"uri\">https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCTs061210040<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13256-025-05562-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:25:56Z","timestamp":1759173956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The safety and efficacy of finasteride for transgender men with androgenetic alopecia: a case series"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-7990","authenticated-orcid":false,"given":"Yusuke","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Moriwake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sadahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Bekku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Edamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"Suppl 1","key":"5562_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","volume":"23","author":"E Coleman","year":"2022","unstructured":"Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, et\u00a0al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgender Health. 2022;23(Suppl 1):S1\u2013259. https:\/\/doi.org\/10.1080\/26895269.2022.2100644.","journal-title":"Int J Transgender Health"},{"key":"5562_CR2","volume-title":"Guidelines for Diagnosis and Treatment of Gender Dysphoria, 5th Edition [in Japanese]","author":"Japanese Society of Psychiatry and Neurology","year":"2024","unstructured":"Japanese Society of Psychiatry and Neurology. Guidelines for Diagnosis and Treatment of Gender Dysphoria, 5th Edition [in Japanese]. Tokyo: Japanese Society of Psychiatry and Neurology; 2024."},{"issue":"1","key":"5562_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1210\/er.2018-00011","volume":"40","author":"G T'Sjoen","year":"2019","unstructured":"T\u2019Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev. 2019;40(1):97\u2013117. https:\/\/doi.org\/10.1210\/er.2018-00011.","journal-title":"Endocr Rev"},{"key":"5562_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211051546","volume":"9","author":"S Korpaisarn","year":"2021","unstructured":"Korpaisarn S, Chiewchalermsri D, Arunakul J, Chinthakanan O, Poomthavorn P, Sriphrapradang C. Effects of testosterone treatment on transgender males: a single-institution study. SAGE Open Med. 2021;9: 20503121211051546. https:\/\/doi.org\/10.1177\/20503121211051546.","journal-title":"SAGE Open Med"},{"issue":"2","key":"5562_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esxm.2020.100306","volume":"9","author":"T Kirisawa","year":"2021","unstructured":"Kirisawa T, Ichihara K, Sakai Y, Morooka D, Iyoki T, Masumori N. Physical and psychological effects of gender-affirming hormonal treatment using intramuscular testosterone enanthate in Japanese transgender men. Sex Med. 2021;9(2): 100306. https:\/\/doi.org\/10.1016\/j.esxm.2020.100306.","journal-title":"Sex Med"},{"key":"5562_CR6","unstructured":"Asfour L, Cranwell W, Sinclair R. Male androgenetic alopecia. In: Feingold KR, Ahmed SF, Anawalt B, et\u00a0al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. 2023"},{"issue":"1","key":"5562_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1346-8138.2011.01378.x","volume":"39","author":"A Sato","year":"2012","unstructured":"Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27\u201332.","journal-title":"J Dermatol"},{"issue":"7","key":"5562_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/ced.13184","volume":"42","author":"OM Moreno-Arrones","year":"2017","unstructured":"Moreno-Arrones OM, Becerra A, Vano-Galvan S. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Clin Exp Dermatol. 2017;42(7):743\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"5562_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/00007611-197511000-00009","volume":"68","author":"OT Norwood","year":"1975","unstructured":"Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359\u201365. https:\/\/doi.org\/10.1097\/00007611-197511000-00009.","journal-title":"South Med J"},{"key":"5562_CR10","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published November 27, 2017."},{"key":"5562_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-642-81650-5_42","volume-title":"Hair Research","author":"I Takashima","year":"1981","unstructured":"Takashima I, Iju M, Sudo M. Alopecia Androgenetica \u2014 Its Incidence in Japanese and Associated Conditions. In: Orfanos CE, Montagna W, St\u00fcttgen G, editors. Hair Research. Berlin: Springer; 1981. p. 287\u201398."},{"issue":"1","key":"5562_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-017-1280-y","volume":"57","author":"F Lolli","year":"2017","unstructured":"Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et\u00a0al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9\u201317. https:\/\/doi.org\/10.1007\/s12020-017-1280-y.","journal-title":"Endocrine"},{"issue":"1","key":"5562_CR13","first-page":"15","volume":"149","author":"BM Piraccini","year":"2014","unstructured":"Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15\u201324.","journal-title":"G Ital Dermatol Venereol"},{"issue":"8","key":"5562_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jsxm.2016.02.106","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher AD, Toye K, et\u00a0al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999\u20132011. https:\/\/doi.org\/10.1016\/j.jsxm.2016.02.106.","journal-title":"J Sex Med"},{"issue":"1","key":"5562_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jsm.12366","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, et\u00a0al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014;11(1):222\u20139.","journal-title":"J Sex Med"},{"issue":"8","key":"5562_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s40265-023-01880-x","volume":"83","author":"S Devjani","year":"2023","unstructured":"Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic alopecia: therapy update. Drugs. 2023;83(8):701\u201315. https:\/\/doi.org\/10.1007\/s40265-023-01880-x.","journal-title":"Drugs"},{"issue":"2","key":"5562_CR17","doi-asserted-by":"publisher","first-page":"229.e1","DOI":"10.1016\/j.ajog.2020.01.059","volume":"223","author":"RL Taub","year":"2020","unstructured":"Taub RL, Ellis SA, Neal-Perry G, Magaret AS, Prager SW, Micks EA. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol. 2020;223(2):229.e1-229.e8. https:\/\/doi.org\/10.1016\/j.ajog.2020.01.059.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"5562_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4158\/EP-2017-0203","volume":"24","author":"KJ Chan","year":"2018","unstructured":"Chan KJ, Jolly D, Liang JJ, Weinand JD, Safer JD. Estrogen levels do not rise with testosterone treatment for transgender men. Endocr Pract. 2018;24(4):329\u201333. https:\/\/doi.org\/10.4158\/EP-2017-0203.","journal-title":"Endocr Pract"},{"issue":"6","key":"5562_CR19","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","volume":"106","author":"MC Madsen","year":"2021","unstructured":"Madsen MC, van Dijk D, Wiepjes CM, Conemans EB, Thijs A, den Heijer M. Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years. J Clin Endocrinol Metab. 2021;106(6):1710\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgab089.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"5562_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaad.2021.08.067","volume":"89","author":"JL Gao","year":"2023","unstructured":"Gao JL, Streed CG Jr., Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. J Am Acad Dermatol. 2023;89(4):774\u201383. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.067.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5562_CR21","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/andr.12881","volume":"9","author":"MS Irwig","year":"2021","unstructured":"Irwig MS. Is there a role for 5\u03b1-reductase inhibitors in transgender individuals? Andrology. 2021;9(6):1729\u201331. https:\/\/doi.org\/10.1111\/andr.12881.","journal-title":"Andrology"},{"issue":"4","key":"5562_CR22","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et\u00a0al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550\u20134.","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05562-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:25:58Z","timestamp":1759173958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05562-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5562"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05562-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Okayama University Certified Review Board prior to initiation (approval no., CRB21-004). It was registered with the Japan Registry of Clinical Trials (jRCTs061210040) as a specified clinical trial involving the use of unapproved or off-label drugs. The participants reviewed the study documents and received individual counseling to ensure an understanding of the study procedures and associated risks prior to providing written consent for study participation in accordance with the Declaration of Helsinki. All patients provided written informed consent to have their data collected in our institutional database used for present and future studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. Copies of the written consent are available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"468"}}